Renal nuclear matrix proteins, polynucleotide sequences encoding them, and their use

Abstract

Nuclear matrix proteins are useful markers for diagnosing and monitoring the stage of malignancy in a cell. Nuclear matrix proteins also are useful targets for the treatment of cell proliferative disorders having a nuclear matrix protein component.

What is claimed is:  
     
         1 . An antibody directed against a nuclear matrix protein or an immunogenic fragment thereof in a human subject, wherein said protein is absent in normal renal cells but present in cancerous renal cells and is selected from the group consisting of: 
 (a) RCCA-1 having a molecular weight of about 53 kD and a pI of about 9.30;    (b) RCCA-2 having a molecular weight of about 32 kD and a pI of about 6.95;    (c) RCCA-3 having a molecular weight of about 27 kD and a pI of about 6.50;    (d) RCCA-4 having a molecular weight of about 20 kD and a pI of about 5.25; and    (e) RCCA-5 having a molecular weight of about 15 kD and a pI of about 6.00 or an immunogenic fragment thereof.    
     
     
         2 . A method for detecting a cell proliferative disorder in a human subject, comprising contacting a cellular component from said subject with said antibody of  claim 1 , which binds to a cellular component associated with a cell proliferative disorder, and detecting whether or not the antibody binds to the cellular component.  
     
     
         3 . The method of  claim 2 , wherein said antibody is polyclonal.  
     
     
         4 . The method of  claim 2 , wherein said antibody is monoclonal.  
     
     
         5 . The method of  claim 2 , wherein said antibody is detectably labeled.  
     
     
         6 . The method of  claim 5 , wherein said label is selected from the group consisting of a radioisotope, a bioluminescent compound, a chemiluminescent compound, a fluorescent compound, a metal chelate, and an enzyme.  
     
     
         7 . The method of  claim 2 , wherein said cellular component is taken from the subject's kidney.  
     
     
         8 . The method of  claim 2 , wherein said cellular component is a protein.  
     
     
         9 . An antibody directed against a nuclear matrix protein or an immunogenic fragment thereof that is present in normal human renal cells but absent in cancerous human renal cells, wherein said protein is RCNL-1 having a molecular weight of about 103 kD and a pI of about 8.30 or an immunogenic fragment thereof.  
     
     
         10 . A method for detecting a cell proliferative disorder in a human subject, comprising contacting a cellular component from said subject with said antibody of  claim 9 , which binds to a cellular component associated with a cell proliferative disorder, and detecting whether or not the antibody binds to the cellular component.  
     
     
         11 . The method of  claim 10 , wherein said antibody is polyclonal.  
     
     
         12 . The method of  claim 10 , wherein said antibody is monoclonal.  
     
     
         14 . The method of  claim 10 , wherein said antibody is detectably labeled.  
     
     
         15 . The method of claim  13 , wherein said label is selected from the group consisting of a radioisotope, a bioluminescent compound, a chemiluminescent compound, a fluorescent compound, a metal chelate, and an enzyme.  
     
     
         16 . The method of  claim 10 , wherein said cellular component is taken from the subject's kidney.  
     
     
         17 . The method of  claim 10 , wherein said cellular component is a protein.